Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutics Development Initiative, 2012
    Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease

    Objective/Rationale:
    Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems,  pre-clinical models of disease and clinical trials in multiple sclerosis and...

  • Clinical Intervention Awards, 2012
    Sublingually Administered APL-130277 Compared to Apokyn in Healthy Volunteers

    Objective/Rationale:
    Apomorphine is an under-utilized medication in Parkinson's disease (PD). Despite its strong efficacy as a rescue medication for intermittent "off" episodes in PD and its rapid...

  • Therapeutics Development Initiative, 2012
    IMD-026259 - An Innovative Drug for Disease-Modifying Treatment of Parkinson´s Disease

    Objective/Rationale:
    IMD-026259 represents a proprietary highly potent and selective small molecule inhibitor of NF-kB pathway and 1 alpha (HIF-1alpha) mediated transcriptional activity. Comprehensive...

  • MJFF Research Grant, 2012
    Gremlin-1, a Putative VTA-derived Neuroprotective Factor in Parkinson's Disease (Supplement)

    Promising Outcomes of Original Grant:
    We have previously postulated that the glycoprotein Gremlin has a neuroprotective role in PD. To test this hypothesis, we sought to develop a gremlin knockout pre...

  • Target Validation, 2012
    Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson’s Disease

    Objective/Rationale:
    Mitochondria are the major energy generators of a cell. Dysfunctional mitochondria are central to the pathology of Parkinson’s Disease (PD).  We hypothesize that improving the...

  • Biomarker Development, 2012
    Cleaved Cerebrospinal Fluid Proteins as Early Biomarkers for Detection of Parkinson’s Disease.

    Objective/Rationale:
    Parkinson’s disease is associated with the appearance of large, intracellular aggregates termed Lewy bodies consisting of damaged, truncated, aggregated and misfolded proteins...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.